. 2020 Mar 28;9(1):16–23. doi: 10.4103/jrpp.JRPP_19_110

Table 2.

Hemoglobin A1c information for hepatitis C virus patients who achieved sustained virologic response and did not achieve sustained virologic response

HbA1c information	Achieved SVR (n=937)			P*
HbA1c information	Pre-index	Post-index	Mean change±SD	P*
Mean±SD	7.5±1.45	7.1±1.25	0.3950±0.93	<0.0001^b
Range (%minimum–%maximum)	4.6–14.3	4.5–14.6	0.3950±0.93	<0.0001^b
HbA1c information	Did not achieve SVR (n=59)			P*
HbA1c information	Pre-index	Post-index	Mean change±SD	P*
Mean±SD	7.4±1.45	7.1±1.10	0.3532±1.18	0.0051^b
Range (%minimum–%maximum)	5.1–10.9	5.1–9.8	0.3532±1.18	0.0051^b
Total mean change between groups			0.0418	0.7441^b

*P<0.05 was defined as a statistically significant difference between the two groups. The following statistical test was used to calculate the P value: ^bWilcoxon test was used for continuous variables. DAA=Direct acting antiviral, HbA1c=Hemoglobin A1c, HCV=Hepatitis C virus, SVR=Sustained virologic response, SD=Standard deviation